Logotype for Mold-Tek Packaging Limited

Mold-Tek Packaging (533080) Q1 24/25 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Mold-Tek Packaging Limited

Q1 24/25 earnings summary

9 Sep, 2026

Executive summary

  • Achieved 7.5% year-over-year and 9.07% sequential volume growth in Q1 FY25, with EBITDA up 2.77% YoY and 2.5% QoQ, though per kg EBITDA declined due to capitalization of costs ending as new plants commenced production.

  • Net sales increased by 11.22% quarter-on-quarter (Q1 FY25 vs Q4 FY24), reaching ₹196.72 crores.

  • Three new plants (Cheyyar, Panipat for ABG, and Sultanpur for pharma) are now operational, but currently running at 15%-25% utilization, expected to ramp up in coming quarters.

  • Commercial supplies to Grasim Industries (Aditya Birla Group) and pharma packaging unit began, with audits completed for ISO and DMF certifications.

  • EBITDA rose by 2.46% quarter-on-quarter to ₹36.67 crores, but profit before tax declined by 6% and net profit dropped by 8% sequentially due to higher depreciation and finance costs.

Financial highlights

  • Q1 revenue: INR 196.5 crores; Paints: INR 83.5 crores, Lubes: INR 46.7 crores, Food: INR 41.6 crores, Qpack: INR 23.8 crores, Pharma: INR 0.8 crores.

  • Q1 volumes: Paints 4,605 tons, Lubes 2,574 tons, Food & FMCG 1,365 tons, Qpack 1,331 tons, Pharma 19 tons.

  • EBITDA for Q1 FY25: ₹36.67 crores, up 2.46% from Q4 FY24 and 2.77% year-over-year.

  • Profit before tax for Q1 FY25: ₹22.19 crores, down 6% from Q4 FY24 and 10.4% year-over-year.

  • Net profit for Q1 FY25: ₹16.53 crores, down 8% from Q4 FY24 and 11.76% year-over-year.

Outlook and guidance

  • Maintains mid-teen (15%) volume growth guidance for FY25, despite Q1 growth of 7.5%, requiring 17%-18% growth in the remaining quarters.

  • Pharma segment expected to contribute INR 15-20 crores in FY25, with significant ramp-up from Q3 onwards and higher EBITDA margins (INR 100-150 per kg depending on product mix).

  • Targeting INR 1,000 crores topline and INR 100 crores PAT by FY26, driven by pharma and ABG ramp-up.

  • Capacity expansion underway at Grasim Industries plants to support anticipated future growth.

  • Commercial supplies in pharma packaging expected to ramp up from October 2024, with new product developments in progress.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more